Conference
DEVELOPMENT AND APPLICATION OF A NEW COST-UTILITY MODEL TO ASSESS THE COST-EFFECTIVENESS OF PALIVIZUMAB FOR THE PREVENTION OF SEVERE RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION IN MODERATE-TO-LATE PRETERM INFANTS
Authors
Carbonell-Estrany X; Fullarton J; Keary I; Rodgers-Gray B; Tarride JE; Paes B
Volume
25
Pagination
pp. S137-S138
Publisher
ELSEVIER SCIENCE INC
Publication Date
December 1, 2022
Conference proceedings
VALUE IN HEALTH
Issue
12
ISSN
1098-3015